Contact:
4008465777
-
About Us
News & Events
-
08-20
Global Expansion | Dongbao Pharm Receives an Approval Letter for Its Insulin Glargine DS Product from Pakistan's DRAP
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Dongbao Pharm" or the "Company") received an approval letter from the Drug Regulatory Authority of Pakistan (DRAP) for its insulin glargine drug su...
-
07-29
Major Breakthrough in Global Expansion | Dongbao Pharm's Insulin Aspart Injection Approved for Marketing by the U.S. FDA
Recently, the insulin aspart injection, developed by Tonghua Dongbao Pharmaceutical Co., Ltd. ("Dongbao Pharm" or "the Company") and Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. ("Kingfrie...
-
07-16
International Milestone | Dongbao Pharm's Insulin Aspart Manufacturing Site Receives an EU GMP Certificate
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Dongbao Pharm" or the "Company") received a GMP certificate for its insulin aspart drug substances (DS), which was issued by the Swedish Medical Pr...
-
05-26
Breakthrough in GLP-1 Global Expansion | Dongbao Pharm's Liraglutide Injection Approved for Marketing in Nicaragua
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Dongbao Pharm" or the "Company") received a drug registration certificate (registration No. 06000760426) for liraglutide injection issued by the Ni...
-
04-23
Global Expansion | Dongbao Pharm Receives an Approval Letter for Its Human Insulin DS Product from Pakistan's DRAP
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Dongbao Pharm" or the "Company") received an approval letter from the Drug Regulatory Authority of Pakistan (DRAP) for its human insulin drug subst...
-
03-14
Global Expansion | Dongbao Pharm Receives a GMP Certificate from Malaysia for Its Human Insulin
Recently, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Dongbao Pharm" or the "Company") officially received a Good Manufacturing Practice (GMP) certificate for its human insulin injection product series...